Finance

Lists
603229:SHA
Zhejiang Ausun Pharmaceutical Co Ltd
CN¥6.54
-1.21%
(-0.080) 1D
Nov 19, 3:00:01 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 603229...
Open
CN¥6.58
High
CN¥6.67
Low
CN¥6.53
Mkt. cap
5.50B
Avg. vol.
4.89M
Volume
2.45M
Dividend
0.98%
Quarterly dividend
CN¥0.02
Ex-dividend date
Jul 17, 2026
52-wk high
CN¥10.81
52-wk low
CN¥6.53
EPS
-CN¥0.00
Shares outstanding
160.00M
No. of employees
1K
Open
CN¥6.58
High
CN¥6.67
Low
CN¥6.53
Mkt. cap
5.50B
Avg. vol.
4.89M
Volume
2.45M
Dividend
0.98%
Quarterly dividend
CN¥0.02
Ex-dividend date
Jul 17, 2026
52-wk high
CN¥10.81
52-wk low
CN¥6.53
EPS
-CN¥0.00
Shares outstanding
160.00M
No. of employees
1K
News stories
From web sources and news partners
About Zhejiang Ausun Pharmaceutical Co Ltd
CEO-
Employees1.33K
FoundedApr 22, 2010
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
146.80M
308.67M
158.94M
142.64M
Cost of goods sold
109.90M
116.10M
101.33M
85.87M
Cost of revenue
109.90M
116.10M
101.33M
85.87M
Research and development expenses
86.27M
30.76M
27.11M
60.47M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
43.63M
25.16M
27.55M
29.65M
Operating expense
122.51M
65.26M
64.56M
84.57M
Total operating expenses
232.42M
181.36M
165.89M
170.44M
Operating income
-85.62M
127.32M
-6.95M
-27.80M
Other non operating income
4.51M
-24.03M
23.70M
-45.33M
EBT including unusual items
-95.44M
107.33M
22.96M
-58.36M
EBT excluding unusual items
-91.98M
110.40M
-10.81M
-29.34M
Income tax expense
-18.98M
10.67M
-214.34K
-10.45M
Effective tax rate
19.89%
9.94%
-0.93%
17.91%
Other operating expenses
-1.11M
-1.44M
5.70M
1.17M
Net income
-76.46M
96.66M
23.18M
-47.91M
Net profit margin
-52.09%
31.32%
14.58%
-33.59%
Earnings per share
-
-
-
-
Interest and investment income
12.21M
9.94M
12.70M
7.95M
Interest expense
-2.47M
-2.83M
-2.59M
-1.84M
Net interest expenses
9.74M
7.12M
10.11M
6.11M
Depreciation and amortization charges
-
-
-
-
EBITDA
-67.40M
145.53M
13.96M
-9.59M
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google apps